ONCOLOGY

Trial included patients with HER2+ LA/mGC in the phase 1 component.

Many advanced gastric cancers are resistant or unresponsive to anti-PD-1 therapies.

Existing third-line therapies have limited benefit in this population.

A case-control study within the Scottish Primary Care Clinical Informatics Unit database and a cohort study from the UK Biobank.

Findings in matched analysis strengthen confidence in observational results.

Meta-analysis of observational studies confirms the association.

Results from a meta-analysis of 10 randomised controlled trials.

The strategy could be especially appropriate with baseline or high risk for peripheral neuropathy.

A large Korean trial finds a test-and-treat strategy in this population works.

The test shows high specificity, sensitivity, and predicted tissue of origin.

Due to a lack of evidence, there is disagreement among guidelines and consensus reports as to whether test and treat H pylori among individuals with a first-degree relative history of gastric cancer.

The drug is the first therapy approved for GIST with PDGFRA exon 18 mutations.

The draft decision is open for public consultation until 24 January

LNR may have more prognostic value than N staging.